Hormone Therapy for Breast Cancer

Introduction

If your breast cancer has been found to be hormone receptor–positive, hormone therapy will most likely be a central part of your treatment plan. Unlike chemotherapy or radiation, which work over weeks or months, hormone therapy works quietly in the background — usually as a daily tablet or a regular injection — for several years. Its job is to take away the hormonal signals that this type of breast cancer needs in order to grow.

This guide is written for women and men who already have a breast cancer diagnosis and are preparing to start hormone therapy, or who have already begun and want a clearer picture of the road ahead. It explains how hormone therapy works, the different drug classes used, what side effects to expect, how progress is monitored, and how this treatment fits alongside surgery, radiation, and other cancer therapies. It also covers practical considerations — bone health, fertility, mood, sexual health — that come up over the years a person spends on this treatment.

Hormone therapy is one of the longest treatment commitments in modern cancer care. Understanding what it does, and what it asks of you, makes that commitment easier to live with.

What Is Hormone Therapy for Breast Cancer?

Hormone therapy (also called endocrine therapy) is a treatment used for breast cancers whose growth is driven by the hormones estrogen and progesterone. These hormones, made naturally in the body, attach to special docking points called receptors on the surface and inside of breast cells. In some breast cancers, those receptors act as accelerators — estrogen lands on them and tells the cancer cell to grow and divide.

If a biopsy shows that a cancer has these receptors, it is labelled:

• Estrogen receptor–positive (ER+) — the cancer cells have receptors for estrogen.
• Progesterone receptor–positive (PR+) — the cancer cells have receptors for progesterone.

Roughly two out of three breast cancers are hormone receptor–positive. Hormone therapy works for these cancers in one of two ways: by blocking the receptors so hormones cannot attach, or by lowering the amount of hormone in the body in the first place. The result is that the cancer cells lose the signal that tells them to grow.

Importantly, hormone therapy is not the same as hormone replacement therapy (HRT) given for menopause. The two work in opposite directions. Hormone therapy for breast cancer aims to reduce the hormonal stimulation of cancer cells.

How Hormone Therapy Works

The estrogen that fuels breast cancer comes from different sources depending on whether a person is premenopausal or postmenopausal. This is why several different drug classes are used — each interferes with estrogen in a different way.

In Premenopausal Women

Before menopause, most estrogen is produced by the ovaries. Hormone therapy in this group may focus on:

• Blocking estrogen receptors on cancer cells directly, so circulating estrogen cannot stimulate them.
• Suppressing the ovaries so they make less estrogen, either with medication or, less commonly, by surgical removal of the ovaries.

In Postmenopausal Women

After menopause, the ovaries no longer produce significant estrogen. Most of the remaining estrogen comes from fat, muscle, and other tissues, where an enzyme called aromatase converts other hormones into estrogen. Hormone therapy in this group often focuses on blocking aromatase, lowering estrogen levels throughout the body.

In Men

Men can also develop hormone receptor–positive breast cancer. Treatment principles are similar, although the choice of drug differs because of differences in how estrogen is produced and processed in male physiology.

Who Receives Hormone Therapy?

Hormone therapy is used only for hormone receptor–positive breast cancers. A receptor test, performed on the biopsy or surgical sample, decides this. Cancers that are receptor-negative do not respond to hormone therapy and are treated differently.

For hormone receptor–positive disease, hormone therapy is used in several situations:

• After surgery (adjuvant therapy): The most common use. Hormone therapy is given for years after surgery to reduce the risk that the cancer comes back, either in the breast area or elsewhere in the body.
• Before surgery (neoadjuvant therapy): In selected cases, hormone therapy is given first to shrink the tumour before surgery. This is more common in older postmenopausal women or when there are reasons to delay or avoid surgery.
• For advanced or metastatic breast cancer: When breast cancer has spread beyond the breast and nearby lymph nodes, hormone therapy can control the disease — sometimes for many years — often in combination with other targeted drugs.
• For ductal carcinoma in situ (DCIS): In some cases of hormone receptor–positive DCIS (a very early, non-invasive form of breast cancer), hormone therapy is offered to reduce the risk of future invasive cancer.

Major guidelines from the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) consistently include hormone therapy as a standard part of treatment for hormone receptor–positive breast cancer. The specific drug and duration depend on menopausal status, the cancer's stage and features, other treatments being given, and individual health factors.

Types of Hormone Therapy

Selective Estrogen Receptor Modulators (SERMs)

SERMs sit on the estrogen receptor of breast cancer cells and block estrogen from attaching. The best-known drug in this class is tamoxifen. Tamoxifen can be used in both premenopausal and postmenopausal women, and in men. It is one of the longest-studied hormone therapies and is a standard option in early hormone receptor–positive breast cancer, typically given for five to ten years depending on individual risk.

Aromatase Inhibitors (AIs)

Aromatase inhibitors block the enzyme that converts other hormones into estrogen in body tissues outside the ovaries. Common AIs include anastrozole, letrozole, and exemestane. Because they do not stop the ovaries from producing estrogen, AIs are used mainly in postmenopausal women. They can be used in premenopausal women only when combined with ovarian suppression. Guidelines from NCCN, ASCO, and ESMO generally describe AIs as a preferred option in postmenopausal hormone receptor–positive disease, often slightly more effective than tamoxifen at reducing recurrence in this group, though with a different side-effect profile.

Ovarian Suppression and Ablation

In premenopausal women, lowering ovarian estrogen production can be a powerful additional step. This is done in two main ways:

• Medication (GnRH or LHRH agonists): Injectable drugs such as goserelin or leuprolide temporarily switch off ovarian estrogen production. The effect reverses when the drug is stopped.
• Surgical removal of the ovaries (oophorectomy): A permanent option used in selected cases, particularly when there is also a high-risk genetic background such as a BRCA mutation.

Ovarian suppression is often combined with either tamoxifen or an aromatase inhibitor in younger women with higher-risk disease, based on evidence from large international trials.

Estrogen Receptor Degraders

Fulvestrant is a drug that binds to the estrogen receptor and causes the receptor itself to be broken down. It is given as a monthly injection and is used mainly in advanced or metastatic hormone receptor–positive breast cancer, often in combination with targeted therapies.

Newer Oral Selective Estrogen Receptor Degraders (SERDs)

Newer oral drugs in this class (such as elacestrant) have been approved in some settings for advanced breast cancer with specific genetic changes in the estrogen receptor. These are used in selected cases after other hormone therapies have stopped working.

Combinations with Targeted Therapy

For advanced hormone receptor–positive breast cancer, hormone therapy is often combined with targeted drugs, most commonly CDK4/6 inhibitors (such as palbociclib, ribociclib, or abemaciclib). Adding these targeted drugs to hormone therapy has been shown to improve disease control compared with hormone therapy alone, and these combinations are now standard in many advanced disease settings. CDK4/6 inhibitors are also increasingly used in selected higher-risk early-stage cancers alongside hormone therapy.

The Treatment Plan and What to Expect

The plan for hormone therapy is built around several decisions: which drug, for how long, alone or in combination, and how to coordinate it with the other parts of breast cancer treatment.

Before Starting

Before hormone therapy begins, the care team will typically arrange:

• Confirmation of hormone receptor status from the biopsy or surgical sample.
• Imaging and staging to clarify the extent of disease.
• Blood tests, including hormone levels in some cases.
• A baseline bone density scan (DEXA) where aromatase inhibitors are planned, since these drugs can affect bone strength.
• A discussion of menopausal status — sometimes menstrual periods alone are not enough to decide this, and blood tests for hormone levels are used to confirm.
• A conversation about fertility, contraception, and pregnancy planning if relevant.

How the Medication Is Taken

Most hormone therapies are taken as a tablet, swallowed once a day, at home. Ovarian suppression drugs are given as an injection, usually every one to three months. Fulvestrant is given as an injection into the muscle, monthly after a loading dose.

Duration

For early hormone receptor–positive breast cancer, hormone therapy is generally continued for five years at minimum. For many people — especially those with higher-risk disease — current guidelines describe extending hormone therapy to seven to ten years as a way to further reduce the risk of late recurrence. The exact length depends on the cancer's features, treatment tolerance, and ongoing risk assessment.

For metastatic disease, hormone therapy is continued as long as it is working and tolerable, sometimes for many years. When one hormone therapy stops controlling the cancer, another may be tried.

How Hormone Therapy Fits with Other Treatments

Hormone therapy is usually one part of a wider plan. In early-stage breast cancer:

• Surgery (lumpectomy or mastectomy) is usually first, sometimes preceded by chemotherapy or hormone therapy.
• Radiation therapy, if needed, generally follows surgery.
• Chemotherapy, when indicated, is typically completed before hormone therapy begins.
• Hormone therapy then continues for years afterwards.

If radiation is given, hormone therapy is sometimes started during radiation and sometimes after; this is decided by the oncology team based on the specific drug and situation. HER2-targeted therapy (for cancers that are also HER2-positive) and hormone therapy can be given together.

Side Effects and How They Are Managed

Common Side Effects

• Hot flashes and night sweats — one of the most common effects, especially in the first months. They often improve over time but may persist.
• Joint and muscle aches — particularly common with aromatase inhibitors. Stiffness in the morning is a frequent complaint.
• Fatigue — often mild to moderate, sometimes significant.
• Mood changes — including low mood, anxiety, and irritability.
• Vaginal dryness and reduced sexual comfort.
• Reduced libido.
• Changes in menstrual periods in premenopausal women — periods may become irregular, lighter, or stop.
• Weight changes — weight gain is reported by many patients, though the precise contribution of the drug versus other factors varies.
• Sleep disturbance.

Less Common but Important Side Effects

• Bone thinning (osteopenia or osteoporosis) — particularly with aromatase inhibitors and with ovarian suppression. Bone density is monitored, and calcium, vitamin D, and bone-protecting medications (such as bisphosphonates or denosumab) may be added.
• Blood clots — a small but real risk with tamoxifen, including deep vein thrombosis and pulmonary embolism.
• Endometrial changes — tamoxifen slightly raises the risk of endometrial (uterine) cancer, especially in postmenopausal women. Any abnormal vaginal bleeding while on tamoxifen should be reported promptly.
• Cardiovascular changes — including changes in cholesterol levels with aromatase inhibitors.
• Cataract risk — a small increase has been observed with tamoxifen.
• Liver function changes — uncommon, monitored with blood tests.

Managing Side Effects

Many side effects can be managed well, and this is one of the most important conversations to keep open with the oncology team. Common approaches include:

• Adjusting the timing of doses (for example, taking tamoxifen at night to reduce daytime hot flashes).
• Switching between drugs in the same class if one is poorly tolerated — for example, switching between the three aromatase inhibitors.
• Switching between drug classes (tamoxifen to an aromatase inhibitor, or vice versa) when appropriate to menopausal status.
• Physical activity, especially weight-bearing exercise, which helps with joint stiffness, fatigue, mood, weight, and bone health.
• Vaginal moisturisers and non-hormonal lubricants for dryness; low-dose vaginal estrogen products are sometimes used in selected cases after careful discussion of risks.
• Medications for hot flashes (certain antidepressants and other non-hormonal options) when symptoms are severe.
• Bone-protecting medications and calcium/vitamin D supplementation.
• Mental health support — counselling, talking therapies, or medication when low mood or anxiety becomes significant.

One of the most important findings from long-term studies is that people who stop hormone therapy early lose some of its protective benefit. If side effects are difficult, it is generally more useful to raise this with the oncology team so adjustments can be made, rather than stopping the drug without discussion.

Response and Monitoring

Because hormone therapy works slowly and quietly, there is no daily signal that it is working. Monitoring is built around regular check-ins and tests.

Monitoring in Early-Stage Disease

For people on adjuvant hormone therapy after surgery, the focus is on:

• Routine oncology visits, typically every three to six months in the first years, then less often.
• Yearly mammograms of the remaining breast tissue.
• Bone density scans every one to two years, particularly with aromatase inhibitors.
• Blood pressure, cholesterol, and general health checks.
• Gynaecological check-ups, especially while on tamoxifen.
• Symptom review at each visit — including new pain, breathlessness, weight loss, or other concerns.

Routine scans of the rest of the body are generally not performed in people without symptoms in early-stage disease, because evidence has not shown that they improve outcomes. Major guidelines focus on symptom-based investigation instead.

Monitoring in Advanced Disease

For metastatic breast cancer on hormone therapy, monitoring is more intensive and includes:

• Regular imaging (CT, MRI, bone scan, or PET-CT depending on the situation).
• Tumour marker blood tests in some cases.
• Symptom review and quality-of-life assessment at each visit.

If the cancer starts to grow again, the oncologist may switch to a different hormone therapy, add a targeted drug, or move to a different class of treatment.

Combining Hormone Therapy with Other Treatments

Hormone therapy is often part of a wider treatment story, especially in advanced disease.

• With CDK4/6 inhibitors: Adding a CDK4/6 inhibitor to hormone therapy has become a standard approach for advanced hormone receptor–positive, HER2-negative breast cancer, based on improvements in disease control shown in large trials.
• With other targeted therapies: Drugs targeting specific genetic changes (such as PIK3CA mutations) may be added in selected cases after testing.
• With bone-protecting drugs: Bisphosphonates or denosumab are often given alongside hormone therapy — both to protect against bone thinning and, in some settings, to reduce recurrence risk in bone.
• With chemotherapy: When chemotherapy is needed, it is generally completed before hormone therapy starts.
• With HER2-targeted therapy: For cancers that are both HER2-positive and hormone receptor–positive, hormone therapy may be given together with HER2-targeted treatment.
• With radiation: Hormone therapy and radiation can be combined; the exact sequence depends on the situation.

Living During and After Treatment

Spending five to ten years on hormone therapy is a significant life chapter. The goal is not just to control or prevent cancer, but to live well during that time.

Daily Life and Work

Most people continue work, study, family responsibilities, and social life while on hormone therapy. Tablets are usually taken at the same time each day, often built into a morning or evening routine. Injections are scheduled at clinic visits.

Bone Health

• Regular weight-bearing exercise such as walking, dancing, or resistance training.
• Adequate calcium and vitamin D, through diet and supplements when advised.
• Avoiding smoking and limiting alcohol.
• Regular bone density monitoring.
• Bone-protecting medications when indicated.

Heart and Metabolic Health

Lower estrogen levels can affect cholesterol and overall cardiovascular health. Regular blood pressure checks, cholesterol monitoring, healthy eating, physical activity, and not smoking become especially important during these years.

Sexual Health and Relationships

Vaginal dryness, reduced libido, and discomfort during intimacy are common and often under-discussed. Non-hormonal moisturisers and lubricants, pelvic floor physiotherapy, and open conversation with the care team can make a real difference. In selected cases, low-dose vaginal estrogen products are considered after individual risk discussion.

Fertility and Pregnancy

Hormone therapy is not used during pregnancy. For premenopausal women who want to have children, fertility preservation (such as freezing eggs or embryos) is generally discussed before treatment begins, especially when chemotherapy is also planned. Recent research has examined temporary pauses in hormone therapy after several years on treatment, in carefully selected women wishing to attempt pregnancy, with close oncology supervision. Whether this is appropriate is an individual decision made with the oncology team.

Reliable, non-hormonal contraception is generally recommended throughout treatment for women who could become pregnant.

Mood and Mental Health

The combination of a cancer diagnosis, treatment fatigue, body changes, and the effects of low estrogen can take a toll on mood. Low mood, anxiety, and irritability are common during hormone therapy. These are not signs of weakness or of failing to cope — they are common, treatable, and worth raising with the care team. Talking therapies, peer support groups, and medication where appropriate all play a role.

Diet, Exercise, and Lifestyle

Regular physical activity has been associated with reduced fatigue, better mood, healthier weight, stronger bones, and possibly improved outcomes in breast cancer survivors. Most guidelines describe a pattern of mixed aerobic and resistance exercise across the week. A balanced diet rich in vegetables, fruits, whole grains, and lean protein is consistently recommended. Maintaining a healthy weight and limiting alcohol are also part of standard survivorship advice.

Adherence Over the Long Run

One of the most important findings in breast cancer research is that the protective effect of hormone therapy depends on actually taking it as prescribed, over the full intended duration. Missed doses, prolonged breaks, or stopping early all reduce benefit. Tools that help include:

• Linking the daily tablet to an established routine (such as brushing teeth).
• Phone reminders or pill organisers.
• Honest conversations with the oncology team when side effects are interfering with daily life, so that adjustments — not silent quitting — become the response.

When the Cancer Comes Back or Does Not Respond

Hormone therapy substantially reduces the risk of breast cancer coming back, but it does not remove it entirely. If the cancer returns, hormone therapy may still play a major role — often by switching to a different drug, adding a targeted therapy, or moving to injectable options like fulvestrant. Genetic testing of the tumour at this point may identify changes (such as ESR1, PIK3CA, or AKT pathway mutations) that guide the next choice of treatment. For some people, chemotherapy or other systemic treatments take over for a time, with hormone therapy returning later in the sequence.

This is part of why long-term follow-up matters, and why new symptoms — persistent bone pain, breathlessness, unexplained weight loss, or new lumps — should always be reported rather than waited out.

Frequently Asked Questions

Is hormone therapy the same as chemotherapy?

No. Chemotherapy uses drugs that damage rapidly dividing cells throughout the body. Hormone therapy works by removing or blocking the hormone signals that certain breast cancers need to grow. Hormone therapy is generally better tolerated than chemotherapy, but it is taken for much longer — years rather than months.

How long will I need to take hormone therapy?

For early-stage hormone receptor–positive breast cancer, the standard duration is at least five years, with many people continuing for seven to ten years depending on individual risk. For advanced or metastatic disease, hormone therapy is continued as long as it is helping and tolerable.

What happens if I stop taking it early?

The benefit of hormone therapy depends on completing the planned course. Stopping early reduces the protective effect against recurrence. If side effects are difficult, the oncology team can often switch drugs or adjust management rather than stop treatment altogether.

Will hormone therapy cause menopause?

In premenopausal women, ovarian suppression and some other treatments can cause temporary or permanent menopause, depending on age, type of treatment, and duration. In already postmenopausal women, hormone therapy does not cause menopause but may intensify symptoms such as hot flashes and vaginal dryness.

Will hormone therapy affect my fertility?

It can. Hormone therapy is not used during pregnancy, and several years on treatment may reduce fertility by age alone. Fertility preservation options are generally discussed before treatment begins for those who wish to have children. Decisions about pausing treatment to attempt pregnancy after several years are made individually with the oncology team.

Can men receive hormone therapy for breast cancer?

Yes. Men with hormone receptor–positive breast cancer are typically offered hormone therapy, most often tamoxifen. Aromatase inhibitors in men are usually combined with another drug to suppress testicular hormone production.

Can I take hormone replacement therapy for menopausal symptoms while on hormone therapy?

Standard hormone replacement therapy (HRT) is generally avoided during and after hormone receptor–positive breast cancer because it can stimulate cancer cells. Non-hormonal options are usually preferred for menopausal symptoms. Low-dose vaginal estrogen for severe dryness is sometimes considered after an individual risk discussion.

Does hormone therapy weaken my bones?

Aromatase inhibitors and ovarian suppression can lower bone density. Bone density is monitored, and calcium, vitamin D, exercise, and bone-protecting medications are used where needed. Tamoxifen has a more neutral or even protective effect on bones in postmenopausal women.

Can I drink alcohol while on hormone therapy?

There is no absolute rule, but limiting alcohol is part of standard advice after breast cancer because alcohol is itself a risk factor for breast cancer recurrence and affects bone health and liver function. Discussing personal limits with the care team is sensible.

What should I do if I miss a dose?

For most oral hormone therapies, a missed dose can be taken when remembered the same day. If it is already close to the next dose, the missed dose is generally skipped rather than doubled. Specific advice should come from the prescribing team.

Conclusion

Hormone therapy is one of the most important long-term tools in the treatment of hormone receptor–positive breast cancer. It works quietly — usually as a daily tablet or a regular injection — to take away the hormonal signals that this kind of cancer needs to grow. Over years, it substantially lowers the chance of the cancer coming back in early-stage disease and helps control advanced disease, often for long stretches of time.

It also asks a great deal: a multi-year commitment, side effects that can shape daily life, and regular monitoring of bones, heart, and overall well-being. The good news is that most side effects can be managed, often by switching between drugs, adjusting timing, or adding supportive treatments. The single most important factor in getting the benefit of hormone therapy is staying on it — and the best way to stay on it is to bring difficulties to the oncology team early, so that adjustments become part of care rather than a reason to stop.

With a clear treatment plan, attentive follow-up, and an ongoing conversation with the care team, hormone therapy can become a steady, manageable part of life after a breast cancer diagnosis rather than a constant burden.